{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:01:44Z","timestamp":1790787704139,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006641","name":"UNICEF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006641","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Global Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\u201cNo regrets\u201d buying \u2013 using Advance Purchase Agreements (APAs) \u2013 has characterized the response to recent pandemics such as Avian flu, Zika Virus, and now COVID-19. APAs are used to reduce demand uncertainty for product developers and manufacturers; to hedge against R&amp;D and manufacturing risks; and to secure availability of products in the face of spiking demand. Evidence on the use of APAs to buy vaccines, medicines, diagnostics, and personal protective equipment during recent pandemics illustrates how these contracts can achieve their intended objectives for buyers. But, transferring risk from suppliers to buyers - as APAs do\u00a0-\u00a0can have consequences, including overbuying and overpaying. Furthermore, the widespread use of APAs by high-income countries has contributed to the striking inequities that have characterized the Swine flu and COVID-19 responses, delaying access to vaccines and other supplies for low- and middle-income countries\u00a0(L&amp;MICs).<\/jats:p><jats:p>We identify seven ways to address some of the risks and disadvantages of APAs, including adoption of a global framework governing how countries enter into APAs and share any resulting supplies; voluntary pooling through joint or coordinated APAs; a concessional-capital-backed facility to allow international buyers and L&amp;MICs to place options on products as an alternative to full purchase commitments; greater collection and sharing of market information to help buyers place smarter APAs; support for a resale market; building in\u00a0mechanisms for donation from the outset; and transitioning away from APAs as markets mature. While a binding global framework could in theory prevent the competitive buying and hoarding that have characterized country\/state responses to pandemics, it will be very challenging to put in place. The other solutions, while less sweeping, can nonetheless mitigate both the inequities associated with the current uncoordinated use of APAs and also some of the risks to individual buyers.<\/jats:p><jats:p>Analysis of recent experiences can provide useful lessons on APAs for the next pandemic. It will be important to keep in mind, however, that these contractual instruments work by transferring risk to the buyer, and that buyers must therefore accept the consequences. In the spirit of \u201cno regrets\u201d purchasing, having bought what hindsight suggests was too much is generally preferable to having bought not enough.<\/jats:p>","DOI":"10.1186\/s12992-022-00851-3","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:26:36Z","timestamp":1655465196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["\u201cNo Regrets\u201d Purchasing in a pandemic: making the most of advance purchase agreements"],"prefix":"10.1186","volume":"18","author":[{"given":"Ian","family":"Thornton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-5866","authenticated-orcid":false,"given":"Gian","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"851_CR1","unstructured":"Jeremy Konyndyk, \u201cIt\u2019s time for a \u2018no regrets\u2019 approach to coronavirus\u201d. The Washington Post, 4th February 2020. Available at: https:\/\/www.washingtonpost.com\/outlook\/2020\/02\/04\/its-time-no-regrets-approach-coronavirus\/. Accessed on 14 Feb 2022."},{"key":"851_CR2","unstructured":"A Towse & H Kettler. (2005). \u201cAdvance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.\u201d. Bulletin of the World Health Organization, 83 (4), 301 - 307. World Health Organization. Accessed at: https:\/\/apps.who.int\/iris\/handle\/10665\/269378. Accessed 21 Feb 2022"},{"issue":"10254","key":"851_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0140-6736(20)31873-0","volume":"396","author":"AL Phelan","year":"2020","unstructured":"Phelan AL, Eccleston-Turner M, Rourke M, Maleche A, Wang C. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access. Lancet. 2020;396(10254):800\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(20)31873-0.","journal-title":"Lancet"},{"key":"851_CR4","unstructured":"Some actors distinguish between advance purchase \u2018agreements\u2019 and \u2018contracts\u2019 \u2013 with the latter considered to be legally binding. However, the term APA has been widely used in the context of pandemic response to refer to legally binding contractual instruments."},{"key":"851_CR5","unstructured":"S Jerving. \u2018The fickle nature of COVID-19 vaccine agreements\u2019. DEVEX. 06 May 2021. Available at: https:\/\/www.devex.com\/news\/the-fickle-nature-of-covid-19-vaccine-agreements-99826. Accessed on 8 March 2022."},{"key":"851_CR6","unstructured":"M. Kremer, A. Towse, & H. Williams. \u201cBriefing Note on Advance Purchase Commitments\u201d. DFID Health Systems Resource Centre. May 2005. Accessed at: https:\/\/www.who.int\/intellectualproperty\/submissions\/MichealKremerKTW_CIPIH_submit_2.pdf?ua=1. Accessed on 15 Feb 2022."},{"key":"851_CR7","unstructured":"Agreements with this kind of conditionality on unpredictable external events can be thought of as \u201csleeping contracts\u201d, as they may lie dormant for years."},{"key":"851_CR8","unstructured":"Susan Athey, Michael Kremer, Christopher Snyder and Alex Tabarrok. \u2018In the Race for a Coronavirus Vaccine, We Must Go Big. Really, Really Big.\u2019 New York Times. 04 May 2020. Available at: https:\/\/www.nytimes.com\/2020\/05\/04\/opinion\/coronavirus-vaccine.html. Accessed on 07 March 2022."},{"issue":"5","key":"851_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jval.2020.12.008","volume":"24","author":"A Towse","year":"2021","unstructured":"Towse A, Chalkidou K, Firth I, Kettler H, Silverman R. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Value In Health. 2021;24(5):625\u201331. https:\/\/doi.org\/10.1016\/j.jval.2020.12.008.","journal-title":"Value In Health"},{"key":"851_CR10","unstructured":"COVAX is global pandemic response collaboration, co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi-The Vaccine Alline, and the World Health Organization (WHO), alongside key delivery partner UNICEF. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world."},{"key":"851_CR11","unstructured":"It is also possible that reducing demand risk for a particular product could accelerate the development of that product whilst in the pipeline. While firm-level decisions on R&D\/production investment are complex and almost always confidential, having finance up front, as well as trust in a future market, may encourage businesses to prioritise a product within their portfolios for potential investment. If financing or prioritization were the rate limiting steps (rather than regulatory hurdles, say) then an APA could accelerate access."},{"key":"851_CR12","doi-asserted-by":"publisher","unstructured":"Contracting modalities of various 'firmnesses\u2019 exist, such as Long-Term Agreements, Advance Market Commitments, and others, but if these are not always sufficiently robust or fit for purpose, an APA can legally \u2018guarantee\u2019 supply. To what extent APAs \u2018guarantee\u2019 supply can be debated. For example, many of the COVAX APAs guaranteed volumes of supply, but not hard delivery dates, which led to suspicions higher paying customers were being prioritized within available production capacity. On the other side Mark Turner (2016) \u2018Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: Lessons from 2009-H1N1\u2019, published in Global Public Health, 11:3,322\u2013335, DOI: https:\/\/doi.org\/10.1080\/17441692.2015.1043743 show that customers who have overbought can often negotiate out of \u2018legally binding\u2019 APAs \u2013 something which must be considered in the risk-reward assumptions on both sides of the deal.","DOI":"10.1080\/17441692.2015.1043743"},{"key":"851_CR13","unstructured":"By guaranteeing revenue and some market share, offering APAs to multiple firms can encourage more developers than might otherwise pursue a particular product to keep going. Given the high overall dropout rate in a product development process, this can also have the overall effect of accelerating development of a product in that category, even if it does not accelerate the R&D on individual products (see above)."},{"key":"851_CR14","unstructured":"Influenza A virus subtype H5N1"},{"issue":"3","key":"851_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/17441692.2015.1043743","volume":"11","author":"M Turner","year":"2016","unstructured":"Turner M. Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: Lessons from 2009\u2013H1N1. Glob Public Health. 2016;11(3):322\u201335. https:\/\/doi.org\/10.1080\/17441692.2015.1043743 Epub 2015 Jul 24 PMID: 26209064.","journal-title":"Glob Public Health"},{"issue":"38","key":"851_CR16","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1016\/j.vaccine.2009.06.034","volume":"27","author":"N Collin","year":"2009","unstructured":"Collin N, de Radigu\u00e8s X. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine. 2009;27(38):5184\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2009.06.034.","journal-title":"Vaccine"},{"key":"851_CR17","unstructured":"The ZIKV outbreak of 2015\u20132016 was initially concentrated in the Americas. In general, the region is characterized by robust surveillance systems including high coverage of fixed site confirmatory testing infrastructure. Accordingly, there was not a large need for POC RDTs across the region. However, the disease\u2019s trajectory was uncertain, and no one was sure whether there would need to be a response to track ZIKV infections in countries with weak surveillance systems; for example, in parts of Africa and Asia where the Aedes aegypti mosquito responsible for spreading ZIKV was also present."},{"key":"851_CR18","unstructured":"UNICEF Evaluation Office. \u2018Innovation Case studies: Zika Virus Diagnostics for Testing at Point-of-Care.\u2019 November 2019. Accessed at: https:\/\/www.unicef.org\/evaluation\/media\/986\/file\/Zika%20Virus%20Diagnostics%20for%20Testing%20at%20Point-of-Care.pdf"},{"key":"851_CR19","unstructured":"Paul A. Wilson, May. Chu, Kristoffer. Gandrup-Marino, Nagwa. Hasanin, Philipp. Kalpaxis, Priya. Sharma, Lama. Suleiman, Jonathan. Weiss and Gian. Gandhi. \u2018UNICEF\u2019s Advance Purchase Commitment for Zika Virus diagnostic tests: design, results, and implications for other products\u2019. Submitted for publication. Available on request."},{"key":"851_CR20","unstructured":"Richard G. Frank Leslie Dach & Nicole Lurie. \u2018It Was The Government That Produced COVID-19 Vaccine Success.\u2019 Health Affairs. 14 May 2021. Available at https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20210512.191448https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20210512.191448. Accessed on 16 Feb 2022."},{"key":"851_CR21","unstructured":"$5.0bn from Allied Market Research, https:\/\/www.alliedmarketresearch.com\/influenza-vaccines-market Accessed 9 March 2022, $5.67bn from Verified Market Research https:\/\/www.verifiedmarketresearch.com\/product\/influenza-vaccine-market\/ Accessed 9 March 2022. Accessed 9 March 2022"},{"key":"851_CR22","doi-asserted-by":"publisher","unstructured":"Accelerating vaccine trials. (2021). Bulletin of the World Health Organization, 99(7), 482\u2013483. https:\/\/doi.org\/10.2471\/BLT.21.020721","DOI":"10.2471\/BLT.21.020721"},{"key":"851_CR23","unstructured":"For example, the Bill and Melinda Gates Foundation has provided $150\u2009m to Gavi, which in turn passed those on to the Serum Institute of India, providing it with \u201cupfront capital\u201d to help it increase manufacturing capacity for AstraZeneca and Novavax vaccines, even before regulatory approval and WHO prequalification had been obtained. https:\/\/www.gavi.org\/news\/media-room\/new-collaboration-makes-further-100-million-doses-covid-19-vaccine-available-low"},{"key":"851_CR24","doi-asserted-by":"publisher","unstructured":"Lythgoe MP, Middleton P. \u2018Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada.\u2019 JAMA Netw Open. 2021;4(6):e2114531. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.14531. Accessed at: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2781352","DOI":"10.1001\/jamanetworkopen.2021.14531"},{"key":"851_CR25","unstructured":"Not all UNICEF purchasing of PPE was through APAs \u2013 these were used for about ~10% of the volumes purchased, to support capacity expansion (as listed in the main body of the paper) and to de-risk production for manufacturers who were new to dealing with UNICEF\/UN procurement"},{"key":"851_CR26","unstructured":"UNICEF Supply. \u2018COVID-19 impact assessment and outlook on personal protective equipment\u2019. 04 May 2020. Available at: https:\/\/www.unicef.org\/supply\/stories\/covid-19-impact-assessment-and-outlook-personal-protective-equipment. Accessed on 16 Feb 2022."},{"key":"851_CR27","doi-asserted-by":"publisher","unstructured":"The RECOVERY Collaborative Group. \u2018Dexamethasone in Hospitalized Patients with Covid-19.\u2019 NEJM, Vol. 384(8), pp 693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436","DOI":"10.1056\/NEJMoa2021436"},{"key":"851_CR28","unstructured":"ACT-Accelerator moves to expand access to dexamethasone for low- and middle-income countries for COVID-19 treatment. 02 July 2020. Available at: https:\/\/unitaid.org\/news-blog\/act-accelerator-moves-to-expand-access-to-dexamethasone-for-low-and-middle-income-countries-for-covid-19-treatment\/#en. Accessed on 17 Feb 2022."},{"key":"851_CR29","unstructured":"UNICEF Supply Division. \u201cReport on the Procurement of health products in support of the \u2018Access to COVID-19 Tools Accelerator -ACT-A)\u201d. Available at: https:\/\/www.unicef.org\/supply\/media\/8291\/file\/Dexamethasone-Inventory-August-2020-November-2021.pdf. Accessed on 02 March 2022."},{"key":"851_CR30","unstructured":"UNICEF internal management data, accurate as of 31 March 2022"},{"key":"851_CR31","unstructured":"T Braithwaite. \u2018We are drowning in vaccine.\u2019 What will revive the market for Covid jabs?. Moderna\u2019s chief says there is \u2018massive oversupply\u2019. Financial times, 22 April 2022. Available at: https:\/\/www.ft.com\/content\/dc35dfc0-94a2-440b-a880-91ba2e39c256. Accessed on 23 April 2022"},{"key":"851_CR32","unstructured":"C Kay, M Kaur Makol, and J Paton. \u2018World Moves From Shortages to Possible Glut of Covid-19 Vaccines\u2019. Bloomberg. March 28, 2022, 5:00 PM EDT. Updated on March 29, 2022, 5:29 AM EDT. Available at: https:\/\/www.bloomberg.com\/news\/articles\/2022-03-28\/world-moves-from-shortages-to-possible-glut-of-covid-19-vaccines. Accessed on 30 March 2022."},{"key":"851_CR33","unstructured":"P Sanjai and Bloomberg. \u2018The world\u2019s biggest vaccine manufacturer has stopped making COVID jabs amid a 200 million dose glut\u2019. FORTUNE. April 22, 2022 5:07 AM EDT. Available at: https:\/\/fortune.com\/2022\/04\/22\/serum-institute-world-biggest-vaccine-manufacturer-stopped-covid-jabs-200-million-dose-glut\/. Accessed on 25 April 2022"},{"key":"851_CR34","unstructured":"M Mishra and M Erman. \u2018J&J pulls COVID vaccine sales forecast due to low demand, supply glut\u2019. Reuters. April 19, 2022 5:31 PM EDT. Available at: https:\/\/www.reuters.com\/business\/johnson-johnson-suspends-sales-forecast-covid-19-vaccine-2022-04-19\/. Accessed on 25 April 2022"},{"key":"851_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/d41586-019-00212-y","volume":"565","author":"L Cnops","year":"2019","unstructured":"Cnops L, De Smet B, Mbala-Kingebeni P, van Griensven J, Ahuka-Mundeke S, Ari\u00ebn KK. Where are the Ebola diagnostics from last time? Nature. 2019;565:419\u201321. https:\/\/doi.org\/10.1038\/d41586-019-00212-y.","journal-title":"Nature"},{"issue":"5","key":"851_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/03063127211035492","volume":"51","author":"K Kameda","year":"2021","unstructured":"Kameda K, Kelly AH, Lezaun J, L\u00f6wy I. Imperfect diagnosis: The truncated legacies of Zika testing. Soc Stud Sci. 2021;51(5):683\u2013706. https:\/\/doi.org\/10.1177\/03063127211035492.","journal-title":"Soc Stud Sci"},{"key":"851_CR37","doi-asserted-by":"publisher","unstructured":"SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. HC Lewis, H Ware, M Whelan, L Subissi, Z Li, X Ma, A Nardone, M Valenciano, B Cheng, K Noel, C Cao, M Yanes-Lane, B Herring, A Talisuna, N Nsenga, T Balde, DA Clifton, M Van Kerkhove, DL Buckeridge, N Bobrovitz, J Okeibunor, RK Arora, I Bergeri, the UNITY Studies Collaborator Group medRxiv 2022.02.14.22270934; doi: https:\/\/doi.org\/10.1101\/2022.02.14.22270934 Accessed 7 March 2022","DOI":"10.1101\/2022.02.14.22270934"},{"key":"851_CR38","unstructured":"Ewen. Callaway. \u2018The unequal scramble for coronavirus vaccines \u2014 by the numbers\u2019. Nature. NEWS EXPLAINER, 24 August 2020. Available at: https:\/\/www.nature.com\/articles\/d41586-020-02450-x. Accessed on 16 Feb 2022"},{"key":"851_CR39","unstructured":"https:\/\/www.imf.org\/en\/Topics\/imf-and-covid19\/IMF-WHO-COVID-19-Vaccine-Tracker Accessed 28 March 2022"},{"key":"851_CR40","unstructured":"https:\/\/ourworldindata.org\/covid-vaccinations Accessed 28 March 2022"},{"key":"851_CR41","unstructured":"European Council of the European Union. \u2018An international treaty on pandemic prevention and preparedness\u2019. Available at: https:\/\/www.consilium.europa.eu\/en\/policies\/coronavirus\/pandemic-treaty\/. Accessed on 6 March 2022."},{"key":"851_CR42","unstructured":"World Health Organization (WHO). \u2018World Health Assembly agrees to launch process to develop historic global accord on pandemic prevention, preparedness and response\u2019. 1 December 2021. Available at: https:\/\/www.who.int\/news\/item\/01-12-2021-world-health-assembly-agrees-to-launch-process-to-develop-historic-global-accord-on-pandemic-prevention-preparedness-and-response. Accessed on 6 March 2022."},{"key":"851_CR43","doi-asserted-by":"publisher","unstructured":"I. Kickbusch & A. Holzscheiter. \u2018Can geopolitics derail the pandemic treaty?\u2019. BMJ 2021; 375 doi: https:\/\/doi.org\/10.1136\/bmj-2021-069129","DOI":"10.1136\/bmj-2021-069129"},{"key":"851_CR44","unstructured":"D.P. Fidler. \u2018The Case Against A Pandemic Treaty\u2019. Think Global Health. 26 November 2021. Available at: https:\/\/www.thinkglobalhealth.org\/article\/case-against-pandemic-treaty. Accessed on 6 March 2022."},{"issue":"24","key":"851_CR45","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1001\/jama.2020.6641","volume":"323","author":"TJ Bollyky","year":"2020","unstructured":"Bollyky TJ, Gostin LO, Hamburg MA. The Equitable Distribution of COVID-19 Therapeutics and Vaccines. JAMA. 2020;323(24):2462\u20133. https:\/\/doi.org\/10.1001\/jama.2020.6641 PMID: 32379268.","journal-title":"JAMA"},{"key":"851_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12992-021-00763-8","volume":"17","author":"F Stein","year":"2021","unstructured":"Stein F. Risky business: COVAX and the financialization of global vaccine equity. Global Health. 2021;17:112. https:\/\/doi.org\/10.1186\/s12992-021-00763-8.","journal-title":"Global Health"},{"key":"851_CR47","unstructured":"https:\/\/ec.europa.eu\/info\/live-work-travel-eu\/coronavirus-response\/public-health\/eu-vaccines-strategy_en Accessed 23 March 2022"},{"key":"851_CR48","unstructured":"See https:\/\/www.tcxfund.com\/about-the-fund\/ for example"},{"key":"851_CR49","unstructured":"At this point, Pfizer-BioNTech, Moderna, AZ, Johnson & Johnson\/Janssen, Sinovac and Sinopharm had all been approved by the WHO or a Stringent Regulatory Authority."},{"key":"851_CR50","unstructured":"UNICEF Vaccine Market Dashboard, https:\/\/www.unicef.org\/supply\/covid-19-vaccine-market-dashboard"},{"key":"851_CR51","doi-asserted-by":"publisher","unstructured":"de Bengy Puyvall\u00e9e, A., Storeng, K.T. COVAX, vaccine donations and the politics of global vaccine inequity. Global Health 18, 26 (2022). https:\/\/doi.org\/10.1186\/s12992-022-00801-z","DOI":"10.1186\/s12992-022-00801-z"},{"key":"851_CR52","unstructured":"M. Apuzzo and& S. Gebrekidan. \u2018Governments Sign Secret Vaccine Deals. Here\u2019s What They Hide.\u2019 New York Times. Published Jan. 28, 2021 and Updated Feb. 24, 2021. Available at: https:\/\/www.nytimes.com\/2021\/01\/28\/world\/europe\/vaccine-secret-contracts-prices.html. Accessed on 6 March 2022."},{"key":"851_CR53","unstructured":"UNICEF Market Dashboard, 9 March 2022. AMC92 countries. Donated and facilitated deliveries ~734m, APAs at ~347m, and cost shared doses at ~113m."},{"key":"851_CR54","doi-asserted-by":"publisher","unstructured":"A Puyvall\u00e9e & K Storeng. \u2018COVAX, vaccine donations and the politics of global vaccine inequity\u2019. Globalization and Health. Vol 18(26). 2022. https:\/\/doi.org\/10.1186\/s12992-022-00801-z","DOI":"10.1186\/s12992-022-00801-z"},{"key":"851_CR55","unstructured":"https:\/\/www.cgdev.org\/blog\/vaccine-mark-counting-more-oda-we-paid-vaccines-illogical-immoral-and-unpopular Accessed 23 March 2022"},{"key":"851_CR56","unstructured":"This could include demand forecasting from potential recipients, the donor-recipient matching facility, country readiness support for those donations, ex ante discussion of ODA treatment, etc."},{"key":"851_CR57","doi-asserted-by":"crossref","unstructured":"Kremer, Michael and Levin, Jonathan D. and Snyder, Christopher M., Designing Advance Market Commitments for New Vaccines (December 2020). NBER Working Paper No. w28168, Available at SSRN: https:\/\/ssrn.com\/abstract=3743901 Accessed 28 March 2022","DOI":"10.2139\/ssrn.3744271"}],"container-title":["Globalization and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-022-00851-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12992-022-00851-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-022-00851-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:33:58Z","timestamp":1655465638000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalizationandhealth.biomedcentral.com\/articles\/10.1186\/s12992-022-00851-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1186\/s12992-022-00851-3","relation":{},"ISSN":["1744-8603"],"issn-type":[{"value":"1744-8603","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}